查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1887103

实验室体外诊断 (IVD) 市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察，以及 2024 年至 2032 年的预测

Lab-based IVD Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 140 Pages | 商品交期: 请询问到货日

价格

实验室体外诊断 (IVD) 市场成长驱动因子

全球实验室体外诊断市场仍然是现代医疗保健的重要支柱，其成长动力主要来自慢性病患病率的上升、传染病爆发以及全球向精准医疗的转型。根据最新的产业评估，受医院和临床实验室强劲的诊断需求驱动，该市场到 2024 年的价值将达到 424.2 亿美元。预计2025年将达到448.5亿美元，到2032年将达到664.1亿美元，2025年至2032年的复合年增长率为5.8%。

北美地区凭藉其先进的医疗保健基础设施、高诊断检测率以及罗氏、雅培、赛默飞世尔科技和BD等主要厂商的存在，将在2024年占全球市场39.39%的占有率。对快速、可靠和高度准确的诊断结果日益增长的需求，正在加速对自动化检测平台、分子诊断和下一代定序技术的投资。

市场驱动因素

实验室体外诊断市场的主要驱动因素是全球慢性病和传染病负担的日益恶化。根据世界卫生组织（世卫组织）的数据，2023年将有820万人被诊断出患有结核病（TB），2022年将有750万人被诊断出患有结核病，这表明全球对结核病筛检的需求日益增长。此外，世卫组织报告称，2024年将有2.54亿例乙型肝炎病例和5000万例丙型肝炎病例，这将进一步推动对常规实验室检测的需求。

在新兴市场和已开发市场，实验室诊断工具的可及性持续改善，这得益于人们对早期疾病检测意识的提高、筛检项目的增加以及诸如世卫组织2023年基本诊断清单（EDL）等公共卫生举措的推动。人口老化也加剧了诊断需求，因为老年人更容易患上需要定期监测的慢性病和传染病。

市场限制因子

儘管市场具有很高的成长潜力，但由于一些新兴市场不利的报销政策，该市场仍面临挑战。基因和分子诊断测试的高昂成本限制了其在非洲、巴西和亚洲部分地区的普及。在中国，省级层级采用不同的报销代码，导致诊断应用出现延迟和不一致。这些因素共同阻碍了先进体外诊断医疗器材（IVD）系统的大规模应用。

市场机会

一个关键机会在于分子诊断（包括次世代定序 (NGS) 和基于 PCR 的技术）的日益普及。各公司正积极寻求 FDA 批准和全球监管认证，以增强其分子检测产品组合。例如，DiaSorin 的 "Simplex COVID-19 & Flu A/B Direct" 检测试剂盒于 2023 年获得 FDA 批准，进一步拓展了其高价值分子检测产品线。从传统诊断转向分子精准诊断工具，正在为改善癌症检测、病毒量测量和基因筛检开闢新的途径。

市场趋势

实验室体外诊断市场的一大趋势是自动化和数位化在实验室工作流程中的应用日益广泛。自动化PCR系统、人工智慧分析仪和先进的血液学系统正在提高检测准确性并缩短週转时间。 2025年4月，Seegene公司宣布开发其下一代自动化平台“CURECA”，旨在简化全球PCR检测流程。

此外，多家公司正在投资个人化诊断解决方案。 2024年2月，Quest Diagnostics推出了MelaNodal Predict，这是一款人工智慧辅助的基因表现检测产品，用于个人化黑色素瘤治疗指导。

依细分市场概述

依产品类型划分

2024年，由于监管审批的增加和检测量的扩大，试剂和耗材占了市场主导地位。预计到 2032 年，设备领域将保持稳定成长，这主要得益于快速检测设备和先进 PCR 系统的日益普及。

依技术划分

2024 年，免疫诊断领域占市场主导地位，这主要得益于罗氏 Elexis HBeAg 定量检测等新型检测方法的推出。分子诊断领域占第二大市场占有率，这主要得益于基于 PCR 的解决方案和新一代定序应用的兴起。

依样本类型划分

预计血液学检测将在 2024 年占市场主导地位，并因其在急性传染病、肿瘤和慢性病评估中的广泛应用而实现最高的复合年增长率。

依应用程式划分

传染病领域在 2024 年仍将保持领先地位，这主要得益于结核病、爱滋病和肝炎等疾病在全球范围内造成的沉重疾病负担。由于癌症病例数量不断增加以及高灵敏度癌症检测技术的推出，肿瘤领域预计将以第二高的复合年增长率增长。

依最终使用者划分

2024年，临床实验室在体外诊断(IVD)市场占主导地位，这主要得益于庞大的患者数量和先进的检测能力。由于慢性病住院率的上升，医院的需求持续强劲。

区域洞察

北美

2024年，北美持续维持市场领先地位，市场规模达到167.1亿美元，主要得益于先进的医疗标准和FDA持续核准的产品。

欧洲

2024年，欧洲位居第二，这主要得益于慢性病的普遍存在以及西门子医疗、希森美康和罗氏等公司的强劲创新势头。

亚太地区

预计到2032年，亚太地区将维持最高的复合年增长率，这主要得益于人们对早期诊断意识的提高以及产品上市数量的增加，其中包括雅培公司于2024年推出的Alinity i.免疫分析模组。

拉丁美洲、中东和非洲

这些地区正经历稳定成长，这主要得益于结核病病例的增加以及自动化化学和血液分析仪的日益普及。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 各国及次区域主要疾病流行情形（2023/2024）
  • 实验室体外诊断产品的技术进步
  • 主要公司新产品发布
  • 主要产业趋势（併购、合作及其他）

第五章：全球实验室体外诊断 (IVD) 市场分析、洞察与预测 (2019-2032)

  • 市场分析、洞察与预测 - 依产品类型划分
    • 仪器
    • 试剂和耗材
  • 市场分析、洞察与预测 - 依技术划分
    • 免疫诊断
      • 酵素连结免疫吸附试验 (ELISA)
      • 萤光免疫分析 (FIA)
      • 快速侦测
      • 其他
    • 临床化学
      • 电解质检测
      • 基础与综合代谢指标检测
      • 肝功能检测
      • 肾功能检测
      • 血脂检测
      • 其他
    • 分子检测诊断
      • 聚合酶炼式反应 (PCR)
      • 原位杂交
      • DNA定序与次世代定序
      • 其他
    • 血液学
    • 其他
  • 市场分析、洞察与预测 - 依样本类型划分
    • 血液
    • 尿液
    • 唾液
    • 组织
    • 其他
  • 市场分析、洞察与预测 - 依应用领域划分
    • 传染病
    • 心臟病学
    • 肿瘤学
    • 胃肠病学
    • 过敏症
    • 自体免疫疾病
    • 产前筛检
    • 其他
  • 市场分析、洞察与预测 - 依最终用途划分用户
    • 医院
    • 临床实验室
    • 其他
  • 市场分析、洞察与预测 - 依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美实验室体外诊断 (IVD) 市场分析、洞察与预测 (2019-2032)

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲实验室体外诊断 (IVD) 市场分析、洞察与预测 (2019-2032)

  • 依国家/地区
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章：亚太地区实验室体外诊断 (IVD) 市场分析、洞察与预测 (2019-2032)

  • 依国家划分
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲实验室体外诊断 (IVD) 市场分析、洞察与预测 (2019-2032)

  • 依国家/地区
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东和非洲实验室体外诊断 (IVD) 市场分析、洞察与预测 (2019-2032)

  • 依国家划分
    • 海湾合作委员会 (GCC)
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析 (2024)
  • 公司简介
    • F.霍夫曼-拉罗氏有限公司
    • 雅培
    • 赛默飞世尔科技公司
    • 希森美康公司
    • 西门子 Healthineers AG
    • BD
    • 凯杰
    • Bio-Rad 实验室有限公司
    • Seegene 公司
    • DiaSorin S.p.A.
    • Quest Diagnostics 公司
Product Code: FBI112985

Growth Factors of lab-based in vitro diagnostics (IVD) Market

The global lab-based in vitro diagnostics (IVD) market remains a foundational pillar of modern healthcare, driven by rising chronic disease prevalence, infectious disease outbreaks, and the global shift toward precision medicine. According to the latest industry assessment, the market was valued at USD 42.42 billion in 2024, supported by strong diagnostic demand across hospitals and clinical laboratories. The market is expected to increase to USD 44.85 billion in 2025, eventually reaching USD 66.41 billion by 2032, advancing at a CAGR of 5.8% throughout 2025-2032.

North America dominated the global market with 39.39% share in 2024, attributed to its advanced healthcare infrastructure, high diagnostic testing rates, and the presence of leading companies such as Roche, Abbott, Thermo Fisher Scientific, and BD. The rising need for rapid, reliable, and high-precision diagnostic results is accelerating investment in automated testing platforms, molecular diagnostics, and next-generation sequencing technologies.

Market Drivers

A key driver for the lab-based IVD market is the growing global burden of chronic and infectious diseases. According to WHO, 8.2 million people were diagnosed with tuberculosis (TB) in 2023, up from 7.5 million in 2022, indicating heightened screening needs worldwide. Additionally, WHO reported in 2024 that 254 million individuals were living with hepatitis B and 50 million with hepatitis C, further boosting demand for routine laboratory testing.

Growing awareness of early disease detection, increasing screening programs, and public health initiatives-such as the WHO's 2023 Essential Diagnostics List (EDL)-continue to improve access to lab-based diagnostic tools across emerging and developed markets. The expanding geriatric population further contributes to diagnostic demand, as elderly individuals are more susceptible to chronic and infectious diseases requiring regular monitoring.

Market Restraints

Despite strong growth potential, the market faces challenges from unfavorable reimbursement policies in several emerging markets. The high cost of genetic and molecular diagnostic tests limits adoption in regions such as Africa, Brazil, and parts of Asia. In China, reimbursement occurs at the provincial level with differing codes, creating delays and inconsistency in diagnostic uptake. These factors collectively restrict large-scale penetration of advanced IVD systems.

Market Opportunities

Major opportunities lie in the rising adoption of molecular diagnostics, including next-generation sequencing (NGS) and PCR-based technologies. Companies are increasingly pursuing FDA approvals and global regulatory certifications to strengthen their molecular testing portfolios. For example, DiaSorin S.p.A. received FDA approval for its Simplex COVID-19 & Flu A/B Direct assay in 2023, expanding its high-value molecular pipeline. The shift from traditional diagnostics to molecular precision tools opens pathways for improved cancer detection, viral load testing, and genetic screening.

Market Trends

A significant trend in the lab-based IVD market is the rising integration of automation and digitalization in laboratory workflows. Automated PCR systems, AI-enabled analyzers, and advanced hematology systems are improving test accuracy and turnaround time. In April 2025, Seegene Inc. announced development of its next-generation automation platform, CURECA, designed to streamline PCR testing processes globally.

Additionally, several companies are investing in personalized diagnostic solutions. In February 2024, Quest Diagnostics launched MelaNodal Predict, an AI-supported gene expression test for personalized melanoma treatment guidance.

Segmental Overview

By Product Type

Reagents & consumables dominated the market in 2024 due to increasing regulatory approvals and growing test volumes. The instruments segment is projected to grow steadily through 2032 with rising adoption of rapid testing devices and advanced PCR systems.

By Technique

Immunodiagnostics led the market in 2024, supported by new assay launches such as Roche's Elecsys HBeAg quant test. The molecular diagnostics segment held the second-largest share, fueled by the growing number of PCR-based solutions and next-generation sequencing applications.

By Sample Type

Blood-based tests dominated the market in 2024 and are expected to grow at the highest CAGR due to widespread usage in acute infections, oncology, and chronic disease assessments.

By Application

Infectious diseases remained the leading segment in 2024, supported by high global burdens of TB, HIV, and hepatitis. Oncology is expected to grow at the second-highest CAGR due to rising cancer cases and the launch of highly sensitive cancer assays.

By End-User

Clinical laboratories dominated the IVD market in 2024, driven by high patient volumes and advanced testing capabilities. Hospitals continued to support significant demand due to increasing hospitalization rates for chronic diseases.

Regional Insights

North America

North America generated USD 16.71 billion in 2024, maintaining market leadership through advanced healthcare standards and continuous product approvals from the FDA.

Europe

Europe ranked second in 2024, supported by chronic disease prevalence and strong innovation momentum from Siemens Healthineers, Sysmex, and Roche.

Asia Pacific

Asia Pacific is expected to record the fastest CAGR through 2032 due to rising early-diagnosis awareness and increased product launches, including Abbott's Alinity i immunoassay module in 2024.

Latin America & Middle East & Africa

These regions show steady growth supported by rising TB cases and increasing adoption of automated chemistry and hematology analyzers.

Conclusion

With the market rising from USD 42.42 billion in 2024 to USD 66.41 billion in 2032, the global lab-based IVD industry is set for significant expansion. Growing infectious disease screening, rapid adoption of molecular diagnostics, automation improvements, and strategic partnerships across companies will continue shaping the future of clinical diagnostics worldwide.

Segmentation By Product Type

  • Instruments
  • Reagents & Consumables

By Technique

  • Immunodiagnostics
    • Enzyme-Linked Immunosorbent Assay (ELISA)
    • Fluorescence Immunoassay (FIA)
    • Rapid test
    • Others
  • Clinical Chemistry
    • Electrolyte Panel
    • Basic and Comprehensive Metabolic Panels
    • Liver Tests
    • Renal Tests
    • Lipid Panel
    • Others
  • Molecular Diagnostics
    • Polymerase Chain Reaction (PCR)
    • In Situ Hybridization
    • DNA Sequencing & Next-Generation Sequencing
    • Others
  • Hematology
  • Others

By Sample Type

  • Blood
  • Urine
  • Saliva
  • Tissue
  • Others

By Application

  • Infectious Diseases
  • Cardiology
  • Oncology
  • Gastroenterology
  • Allergy
  • Autoimmunity
  • Prenatal Screening
  • Others

By End-user

  • Hospitals
  • Clinical Laboratories
  • Others

By Region

  • North America (By Product Type, By Technique, By Sample Type, By Application, By End-user, and By Country/Sub-Region)
    • U.S.
    • Canada
  • Europe (By Product Type, By Technique, By Sample Type, By Application, By End-user, and By Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product Type, By Technique, By Sample Type, By Application, By End-user, and By Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product Type, By Technique, By Sample Type, By Application, By End-user, and By Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product Type, By Technique, By Sample Type, By Application, By End-user, and By Country/Sub-Region)
    • GCC
    • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases, by Key Countries/Sub-regions, 2023/2024
  • 4.2. Technological Advancements in Lab-based IVD Products
  • 4.3. New Product Launches, by Key Players
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

5. Global Lab-based IVD Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Product Type
    • 5.1.1. Instruments
    • 5.1.2. Reagents & Consumables
  • 5.2. Market Analysis, Insights and Forecast - By Technique
    • 5.2.1. Immunodiagnostics
      • 5.2.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)
      • 5.2.1.2. Fluorescence immunoassay (FIA)
      • 5.2.1.3. Rapid test
      • 5.2.1.4. Others
    • 5.2.2. Clinical Chemistry
      • 5.2.2.1. Electrolyte Panel
      • 5.2.2.2. Basic and Comprehensive Metabolic Panels
      • 5.2.2.3. Liver Tests
      • 5.2.2.4. Renal Tests
      • 5.2.2.5. Lipid Panel
      • 5.2.2.6. Others
    • 5.2.3. Molecular Diagnostics
      • 5.2.3.1. Polymerase Chain Reaction (PCR)
      • 5.2.3.2. In Situ Hybridization
      • 5.2.3.3. DNA Sequencing & Next-Generation Sequencing
      • 5.2.3.4. Others
    • 5.2.4. Hematology
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Sample Type
    • 5.3.1. Blood
    • 5.3.2. Urine
    • 5.3.3. Saliva
    • 5.3.4. Tissue
    • 5.3.5. Others
  • 5.4. Market Analysis, Insights and Forecast - By Application
    • 5.4.1. Infectious Diseases
    • 5.4.2. Cardiology
    • 5.4.3. Oncology
    • 5.4.4. Gastroenterology
    • 5.4.5. Allergy
    • 5.4.6. Autoimmunity
    • 5.4.7. Prenatal Screening
    • 5.4.8. Others
  • 5.5. Market Analysis, Insights and Forecast - By End-user
    • 5.5.1. Hospitals
    • 5.5.2. Clinical Laboratories
    • 5.5.3. Others
  • 5.6. Market Analysis, Insights and Forecast - By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Lab-based IVD Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Product Type
    • 6.1.1. Instruments
    • 6.1.2. Reagents & Consumables
  • 6.2. Market Analysis, Insights and Forecast - By Technique
    • 6.2.1. Immunodiagnostics
      • 6.2.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)
      • 6.2.1.2. Fluorescence immunoassay (FIA)
      • 6.2.1.3. Rapid test
      • 6.2.1.4. Others
    • 6.2.2. Clinical Chemistry
      • 6.2.2.1. Electrolyte Panel
      • 6.2.2.2. Basic and Comprehensive Metabolic Panels
      • 6.2.2.3. Liver Tests
      • 6.2.2.4. Renal Tests
      • 6.2.2.5. Lipid Panel
      • 6.2.2.6. Others
    • 6.2.3. Molecular Diagnostics
      • 6.2.3.1. Polymerase Chain Reaction (PCR)
      • 6.2.3.2. In Situ Hybridization
      • 6.2.3.3. DNA Sequencing & Next-Generation Sequencing
      • 6.2.3.4. Others
    • 6.2.4. Hematology
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Sample Type
    • 6.3.1. Blood
    • 6.3.2. Urine
    • 6.3.3. Saliva
    • 6.3.4. Tissue
    • 6.3.5. Others
  • 6.4. Market Analysis, Insights and Forecast - By Application
    • 6.4.1. Infectious Diseases
    • 6.4.2. Cardiology
    • 6.4.3. Oncology
    • 6.4.4. Gastroenterology
    • 6.4.5. Allergy
    • 6.4.6. Autoimmunity
    • 6.4.7. Prenatal Screening
    • 6.4.8. Others
  • 6.5. Market Analysis, Insights and Forecast - By End-user
    • 6.5.1. Hospitals
    • 6.5.2. Clinical Laboratories
    • 6.5.3. Others
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Lab-based IVD Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Product Type
    • 7.1.1. Instruments
    • 7.1.2. Reagents & Consumables
  • 7.2. Market Analysis, Insights and Forecast - By Technique
    • 7.2.1. Immunodiagnostics
      • 7.2.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)
      • 7.2.1.2. Fluorescence immunoassay (FIA)
      • 7.2.1.3. Rapid test
      • 7.2.1.4. Others
    • 7.2.2. Clinical Chemistry
      • 7.2.2.1. Electrolyte Panel
      • 7.2.2.2. Basic and Comprehensive Metabolic Panels
      • 7.2.2.3. Liver Tests
      • 7.2.2.4. Renal Tests
      • 7.2.2.5. Lipid Panel
      • 7.2.2.6. Others
    • 7.2.3. Molecular Diagnostics
      • 7.2.3.1. Polymerase Chain Reaction (PCR)
      • 7.2.3.2. In Situ Hybridization
      • 7.2.3.3. DNA Sequencing & Next-Generation Sequencing
      • 7.2.3.4. Others
    • 7.2.4. Hematology
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Sample Type
    • 7.3.1. Blood
    • 7.3.2. Urine
    • 7.3.3. Saliva
    • 7.3.4. Tissue
    • 7.3.5. Others
  • 7.4. Market Analysis, Insights and Forecast - By Application
    • 7.4.1. Infectious Diseases
    • 7.4.2. Cardiology
    • 7.4.3. Oncology
    • 7.4.4. Gastroenterology
    • 7.4.5. Allergy
    • 7.4.6. Autoimmunity
    • 7.4.7. Prenatal Screening
    • 7.4.8. Others
  • 7.5. Market Analysis, Insights and Forecast - By End-user
    • 7.5.1. Hospitals
    • 7.5.2. Clinical Laboratories
    • 7.5.3. Others
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.6.1. Germany
    • 7.6.2. U.K.
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Lab-based IVD Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Product Type
    • 8.1.1. Instruments
    • 8.1.2. Reagents & Consumables
  • 8.2. Market Analysis, Insights and Forecast - By Technique
    • 8.2.1. Immunodiagnostics
      • 8.2.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)
      • 8.2.1.2. Fluorescence immunoassay (FIA)
      • 8.2.1.3. Rapid test
      • 8.2.1.4. Others
    • 8.2.2. Clinical Chemistry
      • 8.2.2.1. Electrolyte Panel
      • 8.2.2.2. Basic and Comprehensive Metabolic Panels
      • 8.2.2.3. Liver Tests
      • 8.2.2.4. Renal Tests
      • 8.2.2.5. Lipid Panel
      • 8.2.2.6. Others
    • 8.2.3. Molecular Diagnostics
      • 8.2.3.1. Polymerase Chain Reaction (PCR)
      • 8.2.3.2. In Situ Hybridization
      • 8.2.3.3. DNA Sequencing & Next-Generation Sequencing
      • 8.2.3.4. Others
    • 8.2.4. Hematology
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Sample Type
    • 8.3.1. Blood
    • 8.3.2. Urine
    • 8.3.3. Saliva
    • 8.3.4. Tissue
    • 8.3.5. Others
  • 8.4. Market Analysis, Insights and Forecast - By Application
    • 8.4.1. Infectious Diseases
    • 8.4.2. Cardiology
    • 8.4.3. Oncology
    • 8.4.4. Gastroenterology
    • 8.4.5. Allergy
    • 8.4.6. Autoimmunity
    • 8.4.7. Prenatal Screening
    • 8.4.8. Others
  • 8.5. Market Analysis, Insights and Forecast - By End-user
    • 8.5.1. Hospitals
    • 8.5.2. Clinical Laboratories
    • 8.5.3. Others
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Lab-based IVD Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Product Type
    • 9.1.1. Instruments
    • 9.1.2. Reagents & Consumables
  • 9.2. Market Analysis, Insights and Forecast - By Technique
    • 9.2.1. Immunodiagnostics
      • 9.2.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)
      • 9.2.1.2. Fluorescence immunoassay (FIA)
      • 9.2.1.3. Rapid test
      • 9.2.1.4. Others
    • 9.2.2. Clinical Chemistry
      • 9.2.2.1. Electrolyte Panel
      • 9.2.2.2. Basic and Comprehensive Metabolic Panels
      • 9.2.2.3. Liver Tests
      • 9.2.2.4. Renal Tests
      • 9.2.2.5. Lipid Panel
      • 9.2.2.6. Others
    • 9.2.3. Molecular Diagnostics
      • 9.2.3.1. Polymerase Chain Reaction (PCR)
      • 9.2.3.2. In Situ Hybridization
      • 9.2.3.3. DNA Sequencing & Next-Generation Sequencing
      • 9.2.3.4. Others
    • 9.2.4. Hematology
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Sample Type
    • 9.3.1. Blood
    • 9.3.2. Urine
    • 9.3.3. Saliva
    • 9.3.4. Tissue
    • 9.3.5. Others
  • 9.4. Market Analysis, Insights and Forecast - By Application
    • 9.4.1. Infectious Diseases
    • 9.4.2. Cardiology
    • 9.4.3. Oncology
    • 9.4.4. Gastroenterology
    • 9.4.5. Allergy
    • 9.4.6. Autoimmunity
    • 9.4.7. Prenatal Screening
    • 9.4.8. Others
  • 9.5. Market Analysis, Insights and Forecast - By End-user
    • 9.5.1. Hospitals
    • 9.5.2. Clinical Laboratories
    • 9.5.3. Others
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Lab-based IVD Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Product Type
    • 10.1.1. Instruments
    • 10.1.2. Reagents & Consumables
  • 10.2. Market Analysis, Insights and Forecast - By Technique
    • 10.2.1. Immunodiagnostics
      • 10.2.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)
      • 10.2.1.2. Fluorescence immunoassay (FIA)
      • 10.2.1.3. Rapid test
      • 10.2.1.4. Others
    • 10.2.2. Clinical Chemistry
      • 10.2.2.1. Electrolyte Panel
      • 10.2.2.2. Basic and Comprehensive Metabolic Panels
      • 10.2.2.3. Liver Tests
      • 10.2.2.4. Renal Tests
      • 10.2.2.5. Lipid Panel
      • 10.2.2.6. Others
    • 10.2.3. Molecular Diagnostics
      • 10.2.3.1. Polymerase Chain Reaction (PCR)
      • 10.2.3.2. In Situ Hybridization
      • 10.2.3.3. DNA Sequencing & Next-Generation Sequencing
      • 10.2.3.4. Others
    • 10.2.4. Hematology
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Sample Type
    • 10.3.1. Blood
    • 10.3.2. Urine
    • 10.3.3. Saliva
    • 10.3.4. Tissue
    • 10.3.5. Others
  • 10.4. Market Analysis, Insights and Forecast - By Application
    • 10.4.1. Infectious Diseases
    • 10.4.2. Cardiology
    • 10.4.3. Oncology
    • 10.4.4. Gastroenterology
    • 10.4.5. Allergy
    • 10.4.6. Autoimmunity
    • 10.4.7. Prenatal Screening
    • 10.4.8. Others
  • 10.5. Market Analysis, Insights and Forecast - By End-user
    • 10.5.1. Hospitals
    • 10.5.2. Clinical Laboratories
    • 10.5.3. Others
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. F. Hoffmann-La Roche Ltd.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. Financials (Based on Availability)
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. SWOT,Etc.
    • 11.2.2. Abbott
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. Financials (Based on Availability)
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. SWOT,Etc.
    • 11.2.3. Thermo Fisher Scientific Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. Financials (Based on Availability)
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. SWOT,Etc.
    • 11.2.4. Sysmex Corporation
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. Financials (Based on Availability)
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. SWOT,Etc.
    • 11.2.5. Siemens Healthineers AG
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. Financials (Based on Availability)
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. SWOT,Etc.
    • 11.2.6. BD
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. Financials (Based on Availability)
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. SWOT,Etc.
    • 11.2.7. QIAGEN
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. Financials (Based on Availability)
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. SWOT,Etc.
    • 11.2.8. Bio-Rad Laboratories, Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. Financials (Based on Availability)
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. SWOT,Etc.
    • 11.2.9. Seegene Inc.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. Financials (Based on Availability)
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. SWOT,Etc.
    • 11.2.10. DiaSorin S.p.A.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. Financials (Based on Availability)
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. SWOT,Etc.
    • 11.2.11. Quest Diagnostics Incorporated
      • 11.2.11.1. Overview
      • 11.2.11.2. Products
      • 11.2.11.3. Financials (Based on Availability)
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. SWOT,Etc.

List of Tables

  • Table 1: Global Lab-based IVD Market Revenue (USD billion) Forecast, by Product Type, 2019-2032
  • Table 2: Global Lab-based IVD Market Revenue (USD billion) Forecast, by Technique, 2019-2032
  • Table 3: Global Lab-based IVD Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2019-2032
  • Table 4: Global Lab-based IVD Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2019-2032
  • Table 5: Global Lab-based IVD Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2019-2032
  • Table 6: Global Lab-based IVD Market Revenue (USD billion) Forecast, by Sample Type, 2019-2032
  • Table 7: Global Lab-based IVD Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 8: Global Lab-based IVD Market Revenue (USD billion) Forecast, by End-user, 2019-2032
  • Table 9: Global Lab-based IVD Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 10: North America Lab-based IVD Market Revenue (USD billion) Forecast, by Product Type, 2019-2032
  • Table 11: North America Lab-based IVD Market Revenue (USD billion) Forecast, by Technique, 2019-2032
  • Table 12: North America Lab-based IVD Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2019-2032
  • Table 13: North America Lab-based IVD Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2019-2032
  • Table 14: North America Lab-based IVD Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2019-2032
  • Table 15: North America Lab-based IVD Market Revenue (USD billion) Forecast, by Sample Type, 2019-2032
  • Table 16: North America Lab-based IVD Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 17: North America Lab-based IVD Market Revenue (USD billion) Forecast, by End-user, 2019-2032
  • Table 18: North America Lab-based IVD Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 19: Europe Lab-based IVD Market Revenue (USD billion) Forecast, by Product Type, 2019-2032
  • Table 20: Europe Lab-based IVD Market Revenue (USD billion) Forecast, by Technique, 2019-2032
  • Table 21: Europe Lab-based IVD Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2019-2032
  • Table 22: Europe Lab-based IVD Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2019-2032
  • Table 23: Europe Lab-based IVD Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2019-2032
  • Table 24: Europe Lab-based IVD Market Revenue (USD billion) Forecast, by Sample Type, 2019-2032
  • Table 25: Europe Lab-based IVD Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 26: Europe Lab-based IVD Market Revenue (USD billion) Forecast, by End-user, 2019-2032
  • Table 27: Europe Lab-based IVD Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 28: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, by Product Type, 2019-2032
  • Table 29: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, by Technique, 2019-2032
  • Table 30: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2019-2032
  • Table 31: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2019-2032
  • Table 32: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2019-2032
  • Table 33: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, by Sample Type, 2019-2032
  • Table 34: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 35: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, by End-user, 2019-2032
  • Table 36: Asia Pacific Lab-based IVD Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 37: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, by Product Type, 2019-2032
  • Table 38: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, by Technique, 2019-2032
  • Table 39: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2019-2032
  • Table 40: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2019-2032
  • Table 41: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2019-2032
  • Table 42: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, by Sample Type, 2019-2032
  • Table 43: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 44: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, by End-user, 2019-2032
  • Table 45: Latin America Lab-based IVD Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 46: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, by Product Type, 2019-2032
  • Table 47: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, by Technique, 2019-2032
  • Table 48: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, by Immunodiagnostics, 2019-2032
  • Table 49: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, by Clinical Chemistry, 2019-2032
  • Table 50: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2019-2032
  • Table 51: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, by Sample Type, 2019-2032
  • Table 52: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 53: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, by End-user, 2019-2032
  • Table 54: Middle East & Africa Lab-based IVD Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Lab-based IVD Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Lab-based IVD Market Value Share (%), by Product Type, 2024 & 2032
  • Figure 3: Global Lab-based IVD Market Value Share (%), by Technique, 2024 & 2032
  • Figure 4: Global Lab-based IVD Market Value Share (%), by Sample Type 2024 & 2032
  • Figure 5: Global Lab-based IVD Market Value Share (%), by Application, 2024 & 2032
  • Figure 6: Global Lab-based IVD Market Value Share (%), by End-user, 2024 & 2032
  • Figure 7: Global Lab-based IVD Market Value (USD billion), by Region, 2024 & 2032
  • Figure 8: North America Lab-based IVD Market Value (USD billion), by Product Type, 2024 & 2032
  • Figure 9: North America Lab-based IVD Market Value Share (%), by Product Type, 2024
  • Figure 10: North America Lab-based IVD Market Value (USD billion), by Technique, 2024 & 2032
  • Figure 11: North America Lab-based IVD Market Value Share (%), by Technique, 2024
  • Figure 12: North America Lab-based IVD Market Value (USD billion), by Sample Type, 2024 & 2032
  • Figure 13: North America Lab-based IVD Market Value Share (%), by Sample Type, 2024
  • Figure 14: North America Lab-based IVD Market Value (USD billion), by Application, 2024 & 2032
  • Figure 15: North America Lab-based IVD Market Value Share (%), by Application, 2024
  • Figure 16: North America Lab-based IVD Market Value (USD billion), by End-user, 2024 & 2032
  • Figure 17: North America Lab-based IVD Market Value Share (%), by End-user, 2024
  • Figure 18: North America Lab-based IVD Market Value (USD billion), By Country, 2024 & 2032
  • Figure 19: North America Lab-based IVD Market Value Share (%), By Country, 2024
  • Figure 20: Europe Lab-based IVD Market Value (USD billion), by Product Type, 2024 & 2032
  • Figure 21: Europe Lab-based IVD Market Value Share (%), by Product Type, 2024
  • Figure 22: Europe Lab-based IVD Market Value (USD billion), by Technique, 2024 & 2032
  • Figure 23: Europe Lab-based IVD Market Value Share (%), by Technique, 2024
  • Figure 24: Europe Lab-based IVD Market Value (USD billion), by Sample Type, 2024 & 2032
  • Figure 25: Europe Lab-based IVD Market Value Share (%), by Sample Type, 2024
  • Figure 26: Europe Lab-based IVD Market Value (USD billion), by Application, 2024 & 2032
  • Figure 27: Europe Lab-based IVD Market Value Share (%), by Application, 2024
  • Figure 28: Europe Lab-based IVD Market Value (USD billion), by End-user, 2024 & 2032
  • Figure 29: Europe Lab-based IVD Market Value Share (%), by End-user, 2024
  • Figure 30: Europe Lab-based IVD Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 31: Europe Lab-based IVD Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 32: Asia Pacific Lab-based IVD Market Value (USD billion), by Product Type, 2024 & 2032
  • Figure 33: Asia Pacific Lab-based IVD Market Value Share (%), by Product Type, 2024
  • Figure 34: Asia Pacific Lab-based IVD Market Value (USD billion), by Technique, 2024 & 2032
  • Figure 35: Asia Pacific Lab-based IVD Market Value Share (%), by Technique, 2024
  • Figure 36: Asia Pacific Lab-based IVD Market Value (USD billion), by Sample Type, 2024 & 2032
  • Figure 37: Asia Pacific Lab-based IVD Market Value Share (%), by Sample Type, 2024
  • Figure 38: Asia Pacific Lab-based IVD Market Value (USD billion), by Application, 2024 & 2032
  • Figure 39: Asia Pacific Lab-based IVD Market Value Share (%), by Application, 2024
  • Figure 40: Asia Pacific Lab-based IVD Market Value (USD billion), by End-user, 2024 & 2032
  • Figure 41: Asia Pacific Lab-based IVD Market Value Share (%), by End-user, 2024
  • Figure 42: Asia Pacific Lab-based IVD Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 43: Asia Pacific Lab-based IVD Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 44: Latin America Lab-based IVD Market Value (USD billion), by Product Type, 2024 & 2032
  • Figure 45: Latin America Lab-based IVD Market Value Share (%), by Product Type, 2024
  • Figure 46: Latin America Lab-based IVD Market Value (USD billion), by Technique, 2024 & 2032
  • Figure 47: Latin America Lab-based IVD Market Value Share (%), by Technique, 2024
  • Figure 48: Latin America Lab-based IVD Market Value (USD billion), by Sample Type, 2024 & 2032
  • Figure 49: Latin America Lab-based IVD Market Value Share (%), by Sample Type, 2024
  • Figure 50: Latin America Lab-based IVD Market Value (USD billion), by Application, 2024 & 2032
  • Figure 51: Latin America Lab-based IVD Market Value Share (%), by Application, 2024
  • Figure 52: Latin America Lab-based IVD Market Value (USD billion), by End-user, 2024 & 2032
  • Figure 53: Latin America Lab-based IVD Market Value Share (%), by End-user, 2024
  • Figure 54: Latin America Lab-based IVD Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 55: Latin America Lab-based IVD Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 56: Middle East & Africa Lab-based IVD Market Value (USD billion), by Product Type, 2024 & 2032
  • Figure 57: Middle East & Africa Lab-based IVD Market Value Share (%), by Product Type, 2024
  • Figure 58: Middle East & Africa Lab-based IVD Market Value (USD billion), by Technique, 2024 & 2032
  • Figure 59: Middle East & Africa Lab-based IVD Market Value Share (%), by Technique, 2024
  • Figure 60: Middle East & Africa Lab-based IVD Market Value (USD billion), by Sample Type, 2024 & 2032
  • Figure 61: Middle East & Africa Lab-based IVD Market Value Share (%), by Sample Type, 2024
  • Figure 62: Middle East & Africa Lab-based IVD Market Value (USD billion), by Application, 2024 & 2032
  • Figure 63: Middle East & Africa Lab-based IVD Market Value Share (%), by Application, 2024
  • Figure 64: Middle East & Africa Lab-based IVD Market Value (USD billion), by End-user, 2024 & 2032
  • Figure 65: Middle East & Africa Lab-based IVD Market Value Share (%), by End-user, 2024
  • Figure 66: Middle East & Africa Lab-based IVD Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 67: Middle East & Africa Lab-based IVD Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 68: Global Lab-based IVD Market Share (%), By Company, 2024